Understanding innate immune response in glioblastoma in search of a way forward.
作者信息
Pant Ayush, Lim Michael
机构信息
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
出版信息
Neuro Oncol. 2020 Apr 15;22(4):444-445. doi: 10.1093/neuonc/noaa038.
Abstract
摘要
相似文献
1
Understanding innate immune response in glioblastoma in search of a way forward.了解胶质母细胞瘤中的先天免疫反应以寻求前进的道路。
Neuro Oncol. 2020 Apr 15;22(4):444-445. doi: 10.1093/neuonc/noaa038.
2
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis.胶质母细胞瘤免疫治疗靶向固有免疫检查点 CD47-SIRPα 轴。
Front Immunol. 2020 Nov 27;11:593219. doi: 10.3389/fimmu.2020.593219. eCollection 2020.
3
An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma.表达全长抗体的溶瘤病毒增强胶质母细胞瘤的抗肿瘤先天免疫反应。
Nat Commun. 2021 Oct 8;12(1):5908. doi: 10.1038/s41467-021-26003-6.
4
Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target.骨桥蛋白介导胶质母细胞瘤相关巨噬细胞浸润，是一个潜在的治疗靶点。
J Clin Invest. 2019 Jan 2;129(1):137-149. doi: 10.1172/JCI121266. Epub 2018 Nov 19.
5
Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues.在人源肺癌组织中，通过检查点抑制激活固有免疫。
Elife. 2021 Aug 18;10:e69578. doi: 10.7554/eLife.69578.
6
The Current Landscape of Immune Checkpoint Blockade in Glioblastoma.胶质母细胞瘤中免疫检查点阻断的现状
Neurosurg Clin N Am. 2021 Apr;32(2):235-248. doi: 10.1016/j.nec.2020.12.003.
7
Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.溶瘤单纯疱疹病毒免疫病毒疗法联合免疫检查点阻断治疗胶质母细胞瘤。
Immunotherapy. 2018 Jul;10(9):779-786. doi: 10.2217/imt-2018-0009.
8
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.巨噬细胞极化通过联合免疫病毒疗法和免疫检查点阻断促进胶质母细胞瘤的根除。
Cancer Cell. 2017 Aug 14;32(2):253-267.e5. doi: 10.1016/j.ccell.2017.07.006.
9
TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.转化生长因子β治疗通过抑制先天免疫反应增强胶质母细胞瘤病毒疗法。
Cancer Res. 2015 Dec 15;75(24):5273-82. doi: 10.1158/0008-5472.CAN-15-0894. Epub 2015 Dec 2.
10
Prolonged response of recurrent -wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab.复发性野生型胶质母细胞瘤对帕博利珠单抗激光间质热疗的长期应答。
CNS Oncol. 2022 Mar 1;11(1):CNS81. doi: 10.2217/cns-2021-0013. Epub 2022 Jan 19.
引用本文的文献
1
Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study.免疫治疗联合放疗治疗复发性恶性脑胶质瘤：一项前瞻性研究结果。
Front Immunol. 2021 May 7;12:632547. doi: 10.3389/fimmu.2021.632547. eCollection 2021.
本文引用的文献
1
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity.靶向敲除髓系细胞中的 PD-1 可诱导抗肿瘤免疫。
Sci Immunol. 2020 Jan 3;5(43). doi: 10.1126/sciimmunol.aay1863.
2
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.机会窗临床试验显示，帕博利珠单抗治疗复发性胶质母细胞瘤患者，优势细胞为免疫抑制型巨噬细胞。
Neuro Oncol. 2020 Apr 15;22(4):539-549. doi: 10.1093/neuonc/noz185.
3
Harnessing innate immunity in cancer therapy.利用先天免疫进行癌症治疗。
Nature. 2019 Oct;574(7776):45-56. doi: 10.1038/s41586-019-1593-5. Epub 2019 Oct 2.
4
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.新辅助抗 PD-1 免疫治疗在复发性胶质母细胞瘤中促进了肿瘤内和全身免疫应答，并带来生存获益。
Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11.
5
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.新辅助纳武利尤单抗改变可切除胶质母细胞瘤的肿瘤免疫微环境。
Nat Med. 2019 Mar;25(3):470-476. doi: 10.1038/s41591-018-0339-5. Epub 2019 Feb 11.
6
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.口服集落刺激因子1受体抑制剂PLX3397治疗复发性胶质母细胞瘤：常春藤基金会早期临床试验联盟II期研究
Neuro Oncol. 2016 Apr;18(4):557-64. doi: 10.1093/neuonc/nov245. Epub 2015 Oct 8.
7
CSF-1R inhibition alters macrophage polarization and blocks glioma progression.CSF-1R 抑制改变巨噬细胞极化并阻断神经胶质瘤进展。
Nat Med. 2013 Oct;19(10):1264-72. doi: 10.1038/nm.3337. Epub 2013 Sep 22.
8
Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma.CD8+ T细胞和CD4+ T细胞的同时浸润是非小细胞肺癌的一个有利预后因素。
Br J Cancer. 2006 Jan 30;94(2):275-80. doi: 10.1038/sj.bjc.6602934.
9
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.成熟髓样细胞在肿瘤微环境中产生的精氨酸酶I会抑制T细胞受体表达和抗原特异性T细胞反应。
Cancer Res. 2004 Aug 15;64(16):5839-49. doi: 10.1158/0008-5472.CAN-04-0465.
10
Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.食管癌内活化CD8(+) T细胞浸润的预后意义
Cancer Res. 2001 May 15;61(10):3932-6.
Zotero 插件